Carotid artery stiffness, high-density lipoprotein cholesterol and inflammation in men with pre-hypertension

Journal of Human Hypertension

Volumn 23, Issue 9, 2009, Pages 590-596

  Heffernan, K S ^a,b   Karas, R H ^b   Kuvin, J T ^b   Jae, S Y ^c   Vieira, V J ^a   Fernhall, B ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c University of Seoul   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY FAT; BODY MASS; BODY PLETHYSMOGRAPHY; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; EXERCISE TEST; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INFLAMMATION; LEUKOCYTE COUNT; MALE; NEUTROPHIL COUNT; NORMAL HUMAN; PREHYPERTENSION; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

BODY COMPOSITION; CAROTID ARTERIES; CHOLESTEROL, HDL; ELASTICITY; HUMANS; HYPERTENSION; INFLAMMATION; MALE; PHYSICAL FITNESS; YOUNG ADULT;

EID: 69549089986     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.7     Document Type: Article

References (51)

1. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988; 8: 737-741.
2. Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. Stroke 1997; 28: 83-87.
3. Jacobs Jr DR, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: The follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990; 131: 32-47.
4. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835-2838.
5. Havlik RJ, Brock D, Lohman K, Haskell W, Snell P, O'Toole M et al. High-density lipoprotein cholesterol and vascular stiffness at baseline in the activity counseling trial. Am J Cardiol 2001; 87: 104-107, A109.
6. Kuvin JT, Patel AR, Sidhu M, Rand WM, Sliney KA, Pandian NG et al. Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. Am J Cardiol 2003; 92: 275-279.
7. Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: Enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002; 144: 165-172.
8. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113: 664-670.
9. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: A longitudinal study. Hypertension 2002; 39: 10-15.
10. Celik T, Iyisoy A, Kursaklioglu H, Turhan H, Cagdas Yuksel U, Kilic S et al. Impaired aortic elastic properties in young patients with prehypertension. Blood Press Monit 2006; 11: 251-255.
11. Arnett DK, Boland LL, Evans GW, Riley W, Barnes R, Tyroler HA et al. Hypertension and arterial stiffness: The Atherosclerosis Risk in Communities Study. ARIC Investigators. Am J Hypertens 2000; 13 317-323.
12. Liao D, Arnett DK, Tyroler HA, Riley WA, Chambless LE, Szklo M et al. Arterial stiffness and the development of hypertension. The ARIC study. Hypertension 1999; 34: 201-206.
13. Zhu H, Yan W, Ge D, Treiber FA, Harshfield GA, Kapuku G et al. Cardiovascular characteristics in American youth with prehypertension. Am J Hypertens 2007; 20: 1051-1057.
14. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
15. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves JW, Hill MN et al. Recommendations for blood pressure measurement in humans: An AHA scientific statement from the Council on High Blood Pressure Research Professional and Public Education Subcommittee. J Clin Hypertens (Greenwich) 2005; 7: 102-109.
16. Kelly R, Hayword C, Ganis J, Daley J, Avolio A, O'Rourke M. Noninvasive registration of the arterial pressure pulse waveform using high-fidelity applanation tonometry. J Vasc Med Biol 1989; 1: 142-149.
17. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: New challenges of the old problem. Arch Intern Med 2004; 164: 2126-2134.
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
19. Greenlund KJ, Croft JB, Mensah GA. Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000. Arch Intern Med 2004; 164: 2113-2118.
20. Qureshi AI, Suri MF, Kirmani JF, Divani AA, Mohammad Y. Is prehypertension a risk factor for cardiovascular diseases? Stroke 2005; 36: 1859-1863.
21. Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol 2007; 100: 1499-1501.
22. Brown DW, Ford ES, Giles WH, Croft JB, Balluz LS, Mokdad AH. Associations between white blood cell count and risk for cerebrovascular disease mortality: NHANES II Mortality Study, 1976-1992. Ann Epidemiol 2004; 14: 425-430.
23. Brown DW, Giles WH, Croft JB. White blood cell count: An independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol 2001; 54: 316-322.
24. Ensrud K, Grimm Jr RH. The white blood cell count and risk for coronary heart disease. Am Heart J 1992; 124: 207-213.
25. Lee CD, Folsom AR, Nieto FJ, Chambless LE, Shahar E, Wolfe DA. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women: Atherosclerosis risk in communities study. Am J Epidemiol 2001; 154: 758-764.
26. Lee YJ, Lee JW, Kim JK, Lee JH, Kim JH, Kwon KY et al. Elevated white blood cell count is associated with arterial stiffness. Nutr Metab Cardiovasc Dis 2008.
27. Smit JJ, Ottervanger JP, Slingerland RJ, Kolkman JJ, Suryapranata H, Hoorntje JC et al. Comparison of usefulness of C-reactive protein versus white blood cell count to predict outcome after primary percutaneous coronary intervention for ST elevation myocardial infarction. Am J Cardiol 2008; 101: 446-451.
28. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
29. Nakanishi N, Sato M, Shirai K, Suzuki K, Tatara K. White blood cell count as a risk factor for hypertension; a study of Japanese male office workers. J Hypertens 2002; 20: 851-857.
30. Friedman GD, Selby JV, Quesenberry Jr CP. The leukocyte count: A predictor of hypertension. J Clin Epidemiol 1990; 43: 907-911.
31. Gillum RF, Mussolino ME. White blood cell count and hypertension incidence. The NHANES I Epidemiologic Follow-up Study. J Clin Epidemiol 1994; 47: 911-919.
32. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-2951.
33. Schillaci G, Pirro M, Pucci G, Ronti T, Vaudo G, Mannarino MR et al. Prognostic value of elevated white blood cell count in hypertension. Am J Hypertens 2007; 20: 364-369.
34. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hypertens 2004; 17: 568-573.
35. King DE, Egan BM, Mainous III AG, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J Clin Hypertens (Greenwich) 2004; 6: 562-568.
36. Duprez DA, Somasundaram PE, Sigurdsson G, Hoke L, Florea N, Cohn JN. Relationship between C-reactive protein and arterial stiffness in an asymptomatic population. J Hum Hypertens 2005; 19: 515-519.
37. Kampus P, Muda P, Kals J, Ristimae T, Fischer K, Teesalu R et al. The relationship between inflammation and arterial stiffness in patients with essential hypertension. Int J Cardiol 2006; 112: 46-51.
38. Kim JS, Kang TS, Kim JB, Seo HS, Park S, Kim C et al. Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. Atherosclerosis 2007; 192 401-406.
39. Kullo IJ, Seward JB, Bailey KR, Bielak LF, Grossardt BR, Sheedy II PF et al. C-reactive protein is related to arterial wave reflection and stiffness in asymptomatic subjects from the community. Am J Hypertens 2005; 18: 1123-1129.
40. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005; 46 1118-1122.
41. Fichtlscherer S, Breuer S, Schachinger V, Dimmeler S, Zeiher AM. C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur Heart J 2004; 25: 1412-1418.
42. Ikeda U, Takahashi M, Shimada K. C-reactive protein directly inhibits nitric oxide production by cytokine-stimulated vascular smooth muscle cells. J Cardiovasc Pharmacol 2003; 42: 607-611.
43. Singh U, Devaraj S, Vasquez-Vivar J, Jialal I. C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol 2007; 43: 780-791.
44. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-919.
45. Ito BR, Schmid-Schonbein G, Engler RL. Effects of leukocyte activation on myocardial vascular resistance. Blood Cells 1990; 16: 145-163; discussion 163-146.
46. Aronson D, Sheikh-Ahmad M, Avizohar O, Kerner A, Sella R, Bartha P et al. C-Reactive protein is inversely related to physical fitness in middle-aged subjects. Atherosclerosis 2004; 176: 173-179.
47. Church TS, Barlow CE, Earnest CP, Kampert JB, Priest EL, SN. Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol 2002; 22: 1869-1876.
48. Church TS, Finley CE, Earnest CP, Kampert JB, Gibbons LW, Blair SN. Relative associations of fitness and fatness to fibrinogen, white blood cell count, uric acid and metabolic syndrome. Int J Obes Relat Metab Disord 2002; 26: 805-813.
49. Boreham CA, Ferreira I, Twisk JW, Gallagher AM, Savage MJ, Murray LJ. Cardiorespiratory fitness, physical activity, and arterial stiffness: the Northern Ireland Young Hearts Project. Hypertension 2004; 44: 721-726.
50. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC. High-density lipoprotein function recent advances. J Am Coll Cardiol 2005; 46: 1792-1798.
51. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008; 51: 2199-2211.